{
    "nct_id": "NCT04607421",
    "official_title": "AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST-LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600E-MUTANT COLORECTAL CANCER",
    "inclusion_criteria": "* Safety Lead-In = Male/female ≥ 18 years old\n* Phase 3 and Cohort 3: Male/female ≥ 16 years old (where permitted locally)\n* Histologically or cytologically confirmed Stage IV CRC that contains BRAF V600E mutation\n* Prior systemic treatment in metastatic setting: 0-1 regimens for Safety Lead In; none for Phase 3 and Cohort 3. (Note: Prior adjuvant or neoadjuvant therapy considered metastatic treatment if relapse/metastasis < 6 month from end of adj/neoadjuvant treatment )\n* Measurable disease (Phase 3 and Cohort 3)/ Measurable or evaluable disease (Safety Lead-in)\n* ECOG PS 0-1\n* Adequate organ function\nHealthy volunteers allowed\nMust have minimum age of 16 Years",
    "exclusion_criteria": "* Tumors that are locally confirmed or unknown MSI-H or dMMR unless participant is ineligible to receive immune checkpoint inhibitors due to a pre-existing medical condition\n* Active bacterial or viral infections in 2 weeks prior to starting dosing\n* Symptomatic brain metastases",
    "miscellaneous_criteria": ""
}